antigens, is associated with neuronal and axonal damage [7] [8] [9] .
EMAP-II is a proinflammatory antiangiogenic cytokine, up-regulated and involved in inflammatory cascades of secondary damage following CNS injury [10, 11] . The expression of EMAP-II is a sensitive marker of microglia/macrophage activation and associated with the reactivation and accumulation /infiltration of microglia/macrophages after injury in the CNS [11] . MHC-II antigens are also an indicator of reactive microglia/macrophages [12] . Expression of MHC-II on microglia/macrophages is induced following a variety of pathological events, including brain trauma [2, 8, 13] . Clusters of microglia with up-regulated MHC-II antigens are observed not only in lesioned areas but also in regions without overt tissue damage and remote from the site of impact following TBI [7, 14] . However, expression pattern of MHC-II following weight-drop induced TBI remains unknown. FTY720 (Fingolimod), 2-amino-2-(2-[4-octylphenyl] ethyl)-1, 3-propanediol hydrochloride, is the first of a new class of immunosuppressive agents: sphingosine 1-phosphate (S1P) receptor agonists and has shown promising immunosuppressive effects in vivo and in vitro [15] [16] [17] . FTY720 functions through a new mechanism, inhibiting lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at S1P receptors. It sequesters the circulating lymphocytes into lymph nodes, resulting in reduced peripheral lymphocyte counts, but does not alter major effector functions of lymphocytes. Therefore, FTY720 is a potent immunosuppressive agent with minor toxicity and is well tolerated by patients. Furthermore, FTY720 has a novel mechanism of action that has not been observed with other immunosuppressive agents and shows a synergism with currently applied immunosuppressive agents. FTY720 has been shown to be highly effective in experimental allotransplantation and autoimmune disease models. Interestingly FTY720 reduces the number of lesions detected by MRI and clinical disease activity in patients with multiple sclerosis [18] . In animal models of multiple sclerosis, FTY720 prevents the onset of disease and reduces established neurological deficits [19] [20] [21] . In addition administration of FTY720 can inhibit macrophage infiltration into inflammatory lesions under pathological conditions, like experimental autoimmune encephalomyelitis and amyloid ␤-protein stimulated monocyte infiltration [22, 23] .
In this study, we have investigated the potential effects of FTY720 on expression patterns of MHC-II and EMAP-II in the first 96 hrs after weight-dropinduced TBI.
Materials and methods

Animal experiments
Lewis rats (8-9 weeks old, 350-400 g, Elevage Janvier, Le Genest-St-Isle, France) were housed with equal daily periods of light and dark and free access to food and water. All procedures were performed in accordance with the published International Health Guidelines under a protocol approved by the local Administration District Official Committee. The number of the rats used and their suffering were minimized.
TBI was induced using a weight-drop contusion model in anesthetized rats as described previously [24, 25] . Briefly, rats were randomly grouped and anesthetized with Ketamin (120 mg/kg)/Rompun (8 mg/kg) and underwent a craniotomy, in which a circular region of the skull (3.0 mm diameter, centered 2.3 mm caudal and 2.3 mm lateral to bregma) was removed over the right somatosensory cortex. A weight-drop device was placed over the dura and adjusted to stop an impact transducer (foot plate) at a depth of 2.5 mm below the dura. Then, a 20 g weight was dropped from 15 cm above the dura, through a guiding tube onto the foot plate. Body temperature was maintained using an overhead heating lamp during surgery. After injury the scalp was closed tightly. Immediately after surgery rats received an intraperitoneal injection of FTY720 (1 mg/kg, in 1 mL saline, once every second day) or 1 mL saline, respectively (vehicle control group). Rats were killed 24, 48 or 96 hrs after TBI. At the end of the experiment, rats (18 TBI rats and 5 normal adult control rats) were deeply anesthetized with Ketamin (120 mg/kg)/Rompun (8 mg/kg) and perfused intracardially with 4°C 4% paraformaldehyde (PFA) in PBS. Brains were quickly removed and post-fixed in 4% PFA overnight at 4°C. A cortical coronal slice containing the contusion site was embedded in paraffin, serially sectioned (3 m) and mounted on silan-covered slides. The sections were numbered and during the following immunostaining the same antibody was applied to sections with the same number. monohyrate/L, pH 6) (Carl Roth, Karlsruhe, Germany). Endogenous peroxidase was inhibited by 1% H2O2 in pure methanol (Merck, Darmstadt, Germany) for 15 min. Sections were incubated with 10% normal pig serum (Biochrom, Berlin, Germany) to block non-specific binding of immunoglobulins and then with the mouse monoclonal antibodies: OX6 for MHC-II (1:100; Camon, Wiesbaden, Germany) or EMAP-II (1:100; BMA, Augst, Switzerland) overnight at 4°C. Antibody binding to tissue sections was visualized with a biotinylated rabbit antimouse IgG F(ab)2 antibody fragment (1:400; DAKO, Hamburg, Germany). Subsequently, sections were incubated with a horseradish peroxidase-conjugated Streptavidin complex for 30 min (1:100; DAKO, Hamburg, Germany), followed by development with diaminobenzidine (DAB) substrate (Fluka, NeuUlm, Germany). Finally, sections were counterstained with Maier's Hemalaun. As negative controls, the primary antibodies were omitted. Blocking studies have been described [26] . To evaluate the lesion histologically, additional sections were stained with Hematoxylin and Eosin (HE).
Double-staining
In double-staining experiments, brain sections were immunolabeled as described above. Then they were once more irradiated in a microwave for 15 min in citrate buffer and were incubated with 10% normal pig serum (Biochrom, Berlin, Germany). Subsequently the sections were incubated with the appropriate second primary monoclonal antibodies for 1 h at room temperature. Three monoclonal antibodies were used: ED1 (1:100; Serotec, Oxford, UK) to localize activated microglia/macrophages, W3/13 (1:50; Serotec, Oxford, UK) to identify T-lymphocytes and OX22 (1:100; Serotec, Oxford, UK) to detect CD45RC expressed by B lymphocytes and a T cell subset. Consecutively, visualization was achieved by adding secondary antibody (biotinylated rabbit antimouse IgG) at a dilution of 1:400 in TBS-BSA for 30 min and then alkaline phophatase-conjugated Avidin complex diluted 1:100 in Tris-BSA for another 30 min. Finally immunostaining was developed with Fast Blue BB salt chromogen-substrate solution, but by omission of counterstaining with Hemalaun.
Evaluation and statistical analysis
After immunostaining, brain sections of each time point after TBI were examined by light microscopy. EMAP-II and MHC-II (OX6) expression was evaluated at the lesioned areas. The numbers of EMAP-II + and MHC-II + cells of every rat brain section were counted in 3 non-overlapping highpower fields (HPFs, ϫ 400 magnification) for each section. The HPFs were selected from lesional areas that had a maximum of positive cells. In each field studied, only positive cells with the nucleus at the focal plane were counted. Results were given as arithmetic means of MHC-II + cells per HPF and standard errors of means (SEM). Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparison tests or non-parametric t test (Graph Pad Prism 4.0 software). For all statistical analyses, significance levels were set at P < 0.05.
Results
Traumatic brain injury
TBI by weight drop is a well-established animal model for brain trauma studies and was used to generate a reproducible cortical injury. In brains of control TBI rats receiving no FTY720, pannecrosis, where no neuronal structures can be observed, emerged 2 days after injury in the ipsilateral somatosensory cortex and selective neuronal loss ventrally adjacent the pannecrosis extended to near the subcortical white matter. Leukocyte infiltration and hemorrhage were observed soon in those pannecrotic areas. A similar pattern of injury was seen in brains of FTY720 treated rats.
MHC-II expression pattern in rat brains following experimental TBI
Expression of MHC-II was detected by OX6 antibody. In normal adult rat brains, only few MHC-II + cells (2.0 ± 0.3 per HPF, n = 5, Fig. 1A ) were observed in subarachnoid and perivascular spaces and no MHC-II immunoreactivity was detected in the parenchyma of normal adult rat brains ( Fig. 2A) , which is in accordance with previous reports [27] A significant accumulation of MHC-II + cells was detected at Day 1 after TBI (6.1 ± 0.4 per HPF, n = 3, P < 0.01; Fig. 1A ) and increased over time up to the end of our observed period, 96 hrs post-TBI (16.3 ± 2.3 per HPF, n = 3, P < 0.01; Fig. 1A ). Accumulated MHC-II + cells were observed mainly in lesional areas and in subarachnoid and perivascular spaces near lesioned areas as early as Day 1 post-TBI, but MHC-II + cells were rarely seen in perilesional and remote areas.
We further characterized MHC-II + cells by doublestaining with monoclonal antibodies against activated microglia/macrophages (ED1), T cells (W3/13) or B cells (OX22). MHC-II + cells almost all co-expressed ED1, but only 2-5% ED1 + cells were double-stained by MHC-II (Fig. 2B) . At the same time, co-labelling by the pan-T-marker W3/13 or the B cell-marker OX22 with MHC-II was rarely seen. In addition, we have not observed any MHC-II + cells with ramified morphology, which is a necessary intermediate phenotype during microglial activation.Therefore, the major cellular sources of MHC-II in the weight-drop TBI model appear to be reactive macrophages. Nevertheless, MHC-II expression only defines a small subpopulation of activated macrophages.
FTY720 treatment reduces MHC-II + and EMAPII + cell accumulation in TBI rat brains
In brains of FTY720 treated TBI rats, numbers of MHC-II + cells was significantly lower (Fig. 2D ) than of saline treated TBI rats (Fig. 2C ) as early as Day 1 (3.4 ± 0.7 per HPF, n = 3, P < 0.01) and up to Day 4 (7.8 ± 2.2 per HPF, n = 3, P < 0.01; Fig. 1A) .
EMAP-II expression was as well analyzed in TBI rats. Significant accumulation of EMAP-II + cells in lesional areas was seen at Day 1 after injury (17.7 ± 4.6 per HPF, n = 3, P < 0.05, compared to normal controls, data submitted and not shown here) and reached maximal numbers by Day 4 (146.3 ± 6.6 per HPF, n = 3, P < 0.01). In brains of FTY720 treated TBI rats, inhibition of EMAP-II + cell accumulation (Fig. 2E and 2F ) was observed at Day 4 compared to saline treated group (85.6 ± 10.2 per HPF in FTY720 group and 146.3 ± 6.6 per HPF in saline control group, n = 3, P < 0.01; Fig. 1B ).
Discussion
Here we have analyzed the early expression pattern of MHC-II in rat TBI induced by a weight-drop model and studied effects of FTY720 on MHC-II and EMAP-II expression. Significant MHC-II + cell accumulation was observed early at 24 hrs after TBI and increased steadily up to 96 hrs during our observation period. The major cellular sources of MHC-II were identified as reactive macrophages by double-staining experiments. FTY720 significantly attenuated accumulation of MHC-II + cells and EMAP-II + cells in the initial stages of lesion development in rat brains following TBI.
MHC-II molecules expressed together with processed antigen and additional co-stimulatory molecules at the surface of antigen-presenting cells are essential to antigen presentation [28] . In normal brains, a subpopulation of roundly shaped macrophages, usually present in the subarachnoid space, VirchowRobin's space and the choroid plexus, are constitutively MHC-II positive [27, 29] . Under a variety of pathogenic events, like intrathecal administration of TNF-␣ and TNF-␥, peripheral nerve axotomy and CNS infection, MHC-II expression is rapidly induced in microglia [12, [30] [31] [32] [33] [34] [35] [36] . Here a slight but significant increase in expression of MHC-II was also observed early following the weight-drop trauma and was restricted to a small sub-population of activated macrophages. Upregulation of MHC-II has been reported in other TBI models but its expression pattern is different from that of the weight-drop model. In a stab wound TBI model, which is characterized by severe invasive mechanical lesions, a much stronger accumulation of MHC-II + cells was observed compared with the weight-drop model and most reactive macrophages/microglia were MHC-II positive at any given time point [37] . In a closed TBI model, which is characterized with diffuse lesion, a much wider distribution of MHC-II + cells was reported [27] . Therefore, MHC-II up-expression is confirmed in different TBI models but its expression patterns are different from each other, indicating that MHC-II defined cell population might play distinguishing roles in different TBI models.
An interesting finding in this investigation is that FTY720 attenuated early accumulation of MHC-II + and EMAP-II + cells after TBI. As mentioned above, MHC-II + cells are reactive macrophages. Further, EMAP-II is a proinflammatory, antiangiogenic cytokine and expressed by activated microglia/macrophages in the parenchyma of the CNS. Increased expression of EMAP-II is considered a sensitive marker of microglia/macrophage activation [10, 11] . Therefore, FTY720 actually suppressed accumulation of reactive microglia/macrophages following TBI. FTY720 is a promising and potent immunosuppressive agent and acts through S1P signalling pathway to sequester lymphocytes into secondary lymphatic tissues and thus away from inflammatory lesions and graft sites [38, 39] . For monocytes/macrophages, depletion of circulating monocytes and alteration of macrophage functions following FTY720 treatment has not been reported. However, under pathological conditions, like experimental autoimmune encephalomyelitis and amyloid ␤-protein stimulated monocyte infiltration, administration of FTY720 inhibits macrophage infiltration to inflammatory lesions [22] . Here we have shown that FTY720 also suppressed reactive microglia/ macrophages accumulation to early lesions of TBI. The general, these suppressive effects of FTY720 on the accumulation of inflammatory cells following TBI could provide a new option to inhibit brain inflammatory reaction following TBI.
Pathological EMAP-II expression triggers the recruitment of macrophages, stimulates leukocyte chemotaxis, induces the expression of certain cytokines and causes endothelial apoptosis [26, [40] [41] [42] [43] . Accumulation of EMAP-II + microglia/macrophages has been observed in regions of neuronal death at the lesion site and in areas of ongoing secondary damage [10] . Following TBI, EMAP-II is involved in causing edema and hypoxia [44, 45] , which are known to alter blood flow rheology leading to microclustering and occlusion of fine microcappilaries resulting in the impairment of CNS parenchymal trophic supply [46] . FTY720 attenuated the accumulation of EMAP-II + cells at Day 4 following TBI, suggesting FTY720 might have protective effects in early TBI.
In summary, we have studied MHC-II expression pattern in the early phase of weight-drop induced TBI. MHC-II expression is different in several TBI models, indicating that MHC-II defined macrophages sub-population might play different roles in different TBI models. Furthermore, FTY720 attenuates early lesional accumulation of EMAP-II + reactive macrophages/microglia and of MHC-II + reactive macrophages in TBI, suggesting that FTY720 could be applied to inhibit brain inflammatory reactions following TBI.
